【正文】 24。o)入組標(biāo)準(zhǔn) T3/T4, N0/Nx 前列腺癌 或 T2 前列腺癌 PSA 40 181。,ADT 177。27:16576. 3Saad F, Gleason DM, Murray R. J Natl Cancer Inst. 2002。 wǎnɡ)或目前未接受 雙磷酸鹽治療 (N = 1901),Fizazi K, et al. ASCO 2010. Abstract LBA4507.,Denosumab vs. 唑來膦酸CRPC骨轉(zhuǎn)移 患者(hu224。n)的時(shí)間,Fizazi K, et al. ASCO 2010. Abstract LBA4507. Reprinted with permission.,1.00,0.75,0.50,0.25,0,0,3,6,9,12,15,18,21,24,27,未出現(xiàn)骨相關(guān)事件的患者(hu224。,內(nèi)容(n232。前瞻、雙盲、安慰劑對(duì)照的III期研究,第四十一頁，共四十一頁。nzhǎn)的患者比例,0,3,6,9,12,15,18,21,24,27,月,Subjects at risk:,1.00,0.25,0.50,0.75,Denosumab,Zoledronic acid,HR = 1.06 (95% CI: 0.95, 1.18),P = 0.30,第三十九頁，共四十一頁。nzhě)分布,Denosumab組: 950,唑來膦酸組: 951,隨機(jī)(su237。)及相關(guān)臨床研究,RANKL的高親和性人源化單抗 皮下注射給藥 特異性:不與TNFα, TNFβ, TRAIL, 或CD40L結(jié)合 I抑制破骨細(xì)胞的形成(x237。njiū)背景,超過75%的進(jìn)展期前列腺癌患者出現(xiàn)骨轉(zhuǎn)移1 骨轉(zhuǎn)移導(dǎo)致成骨細(xì)胞介導(dǎo)的骨破壞 臨床(l237。b236。,治療(zh236。,去勢(shì)治療 + 放療(f224。nzhǎn)生存,Kelly WK, et al. ASCO 2010. Abstract LBA4511.,1.0,生存(shēngc98(12):25928 3Picus et al. Cancer in press,第五頁，共四十一頁。i sh249。),CALGB 90401: 化療177。,地塞米松(d236。n)概率,0.8,0.6,0.4,0.2,0,0,6,12,18,24,30,36,42,月,安慰劑 + CT,貝伐 + CT,526,303,134,75,34,8,4,0,524,381,194,97,44,15,5,1,HR: 0.77 (95% CI: 0.680.88) Log rank P .0001,安慰劑 + CT,貝伐單抗+ CT,中位無進(jìn)展(j236。nɡ li225。li225。ng)特異性生存（DSS）,Warde PR, et al. ASCO 2010. Abstract CRA4504. Reprinted with permission.,100,80,60,40,20,0,0,3,6,9,Yrs,HR: 0.57 (95% CI: 0.370.78。n chu225。ngch233。 jī): 1901,終止(zhōngzhǐ)治療原因 死亡 269 (28.3%) 退出 164 (17.2%) 疾病進(jìn)展 113 (11.9%) 不良反應(yīng) 43 (4.5%) 其他 154 (16.2%),終止治療原因 死亡 294 (30.9%) 退出 147 (15.5%) 疾病進(jìn)展 117 (12.3%) 不良反應(yīng) 56 (5.9%) 其他 108 (11.4%),終止治療: 743 (78.1%),終止治療: 722 (76.0%),第三十五頁，共四十一頁。,總生存(shēngc,。nzhě)比例,0,3,6,9,12,15,18,21,24,27,30,Subjects at risk:,1.00,0.25,0.50,0.75,HR = 1.03 (95% CI: 0.91, 1.17),Denosumab,唑來膦酸,月,P = 0.65,第四十頁，共四十一頁。ji224。,Denosumab 120 mg SC + 安慰劑 IV q4w (n = 950),唑來膦酸 4 mg IV + 安慰劑 SC q4w (n = 951),CRPC骨轉(zhuǎn)移患者, 既往(j236。 12(20 Suppl)